Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 3
2012 2
2013 2
2014 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW. Ban-Hoefen M, et al. Br J Haematol. 2013 Nov;163(4):487-95. doi: 10.1111/bjh.12570. Epub 2013 Sep 20. Br J Haematol. 2013. PMID: 24111533 Free article.
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.
Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M, Milner L, Phillips G, Friedberg JW. Ban-Hoefen M, et al. Leuk Lymphoma. 2012 May;53(5):830-5. doi: 10.3109/10428194.2011.631637. Epub 2011 Dec 6. Leuk Lymphoma. 2012. PMID: 22023518 Free PMC article. Clinical Trial.
The impact of rituximab on the outcome of high-dose therapy and autologous stem cell transplant (HD-ASCT) for transformed non-Hodgkin lymphoma (NHL) has not been previously described. ...
The impact of rituximab on the outcome of high-dose therapy and autologous stem cell transplant (HD-ASCT) for transformed non- …
Expression of DNA mismatch repair proteins in transformed non-Hodgkin's lymphoma: relationship to smoking.
Nandi S, Yu J, Burger AM, Reinert LS, Gartenhaus RB. Nandi S, et al. Leuk Lymphoma. 2006 Sep;47(9):1806-12. doi: 10.1080/10428190600652137. Leuk Lymphoma. 2006. PMID: 17064992
It has been hypothesized that defects in DNA-mismatch repair are associated with smoking in certain types of transformed non-Hodgkin lymphoma (NHL). We have analyzed biopsy samples from two indolent B-cell lymphomas, follicular lymphoma (FL) and chroni …
It has been hypothesized that defects in DNA-mismatch repair are associated with smoking in certain types of transformed non- …
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM, Allen MS, Loberiza FR Jr, Bociek RG, Bierman PJ, Armitage JO, Vose JM. William BM, et al. Biol Blood Marrow Transplant. 2014 Apr;20(4):536-42. doi: 10.1016/j.bbmt.2014.01.004. Epub 2014 Jan 14. Biol Blood Marrow Transplant. 2014. PMID: 24434781 Free article. Clinical Trial.
A phase I/II trial was designed to evaluate the safety and efficacy of adding bortezomib to standard BEAM (BCNU, etoposide, cytarabine, melphalan) and autologous hematopoietic stem cell transplantation (ASCT). Eligible patients had relapsed/refractory indolent or transformed …
A phase I/II trial was designed to evaluate the safety and efficacy of adding bortezomib to standard BEAM (BCNU, etoposide, cytarabine, melp …
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.
Buchegger F, Antonescu C, Helg C, Kosinski M, Prior JO, Delaloye AB, Press OW, Ketterer N. Buchegger F, et al. J Nucl Med. 2011 Jun;52(6):896-900. doi: 10.2967/jnumed.111.087460. Epub 2011 May 13. J Nucl Med. 2011. PMID: 21571800 Free article.
The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transformed non-Hodgkin lymphoma. METHODS: More than 9 y ago, we treated 12 indolent and 4 transformed, relapsed or refrac …
The purpose of our study was to update the safety and efficacy results of radioimmunotherapy in relapsed or resistant indolent or transfo …
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, Li J, Pietronigro D, Ervin-Haynes A, Reeder CB. Czuczman MS, et al. Br J Haematol. 2011 Aug;154(4):477-81. doi: 10.1111/j.1365-2141.2011.08781.x. Epub 2011 Jun 28. Br J Haematol. 2011. PMID: 21707581 Free article. Clinical Trial.
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.
Roy R, Evens AM, Patton D, Gallot L, Larson A, Rademaker A, Cilley J, Spies S, Variakojis D, Gordon LI, Winter JN. Roy R, et al. Leuk Lymphoma. 2013 Mar;54(3):497-502. doi: 10.3109/10428194.2012.722215. Epub 2012 Sep 11. Leuk Lymphoma. 2013. PMID: 22906230 Clinical Trial.
This phase I trial was designed to determine the maximum tolerated dose (MTD) of weekly bortezomib induction combined with Y-90-ibritumomab tiuxetan followed at the time of count recovery by weekly bortezomib consolidation in patients with relapsed/refractory follicular or tra …
This phase I trial was designed to determine the maximum tolerated dose (MTD) of weekly bortezomib induction combined with Y-90-ibritumomab …